20:04 EST Cathie Wood’s ARK Investment bought 178.1K shares of Crispr Therapeutics (CRSP) today
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRSP:
- Cathie Wood’s ARK Investment bought 409.5K shares of Crispr Therapeutics today
- Crispr Therapeutics price target lowered to $53 from $59 at Stifel
- Crispr Therapeutics price target lowered to $55 from $59 at Barclays
- CRISPR Therapeutics Advances with Solid Financials and Approvals
- Crispr Therapeutics reports Q3 EPS ($1.01), consensus ($1.42)